Evidence map›Paper›PMID 42009839›Full record

ArticleNPJ precision oncology2026

Sox2 protein stability is enhanced by BRafV600E and Pten deletion in adult neural stem/progenitor cells.

Eugenia Guida, Ambra Colopi, Valeriana Cesarini, Marco Pieraccioli, Luca Mignini, Silvia Di Cesare, Maurizio Martini, Marco Gessi, Maurizio Salvati, Silvia Kirsten Nicolis and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in NPJ precision oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Eugenia Guida *Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. eugenia.guida@uniroma2.it.
Ambra Colopi *Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
Valeriana CesariniNational Research Council-Institute of Genetics and Biomedical Research, Milan Unit, Italy.
Marco PieraccioliDepartment of Neuroscience, Section of Human Anatomy, Catholic University of the Sacred Heart, Rome, Italy.
Luca MigniniDepartment of Molecular Genetics and Functional Genomics, Ospedale Pediatrico Bambino Gesù, IRCCS, Rome, Italy.
Silvia Di CesareDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Maurizio MartiniDepartment of Adult and Developmental Human Pathology "Gaetano Barresi"; Unit of Pathology, University of Messina, Messina, Italy.
Marco GessiNeuropathology Unit, Fondazione Policlinico Universitario "A. Gemelli", IRCCS and Department of Life Sciences and Public Health, Catholic University of the Sacred Heart, Rome, Italy.
Maurizio SalvatiDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Silvia Kirsten NicolisDepartment of Biotechnologies and Biosciences, University of Milan Bicocca, Milan, Italy.
Maria CaffoDepartment of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
Emmanuele Angelo JanniniDepartment of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Susanna DolciDepartment of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy. dolci@uniroma2.it.

Funding

Ministero dell'Università e della Ricerca Prin 2022AWB8T4Ministero dell'Università e della Ricerca Prin 2022X4FWZ5
6 · The paper itself

Abstract

BRAF mutations are oncogenic drivers present in about 7% of human cancers, with the V600E substitution being the most frequent. In the nervous system, BRAFV600E has been identified in both low- and high-grade gliomas (LGG and HGG) and in tumors of the peripheral nervous system. To investigate the mechanisms underlying BRafV600E-driven tumorigenesis, we generated a mouse model in which the BRafV600E mutation and Pten deletion can be induced through the Sox2-CreERT2 system. This inducible deleter is active in adult neural stem/progenitor cells (aNSPCs) and Schwann cell precursors (SCPs). In this model, BRafV600E-mutated/Pten-deleted telencephalic aNSPCs give rise to diffuse LGG with oligodendroglioma-like features resembling the human diffuse LGG, MAPK pathway-altered subtype. In contrast, mutated SCPs develop schwannomas, cutaneous neurofibromas, and malignant peripheral nerve sheath tumors (MPNSTs). Sox2 deletion in BRafV600E/Pten

Identifiers

PMID42009839
PMCPMC13280168

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.